Trial Profile
An Open-Label, Extension, Phase III Study to Evaluate the Long-Term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA220JP or MRA221JP.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 29 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2009 Planned end date changed from Jan 2009 to Jul 2009 as reported by ClinicalTrials.gov.
- 04 Dec 2005 New trial record.